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Key messages
What is the key question?
 ► Can patient- nominated lay carers provide 
intramuscular injections at home to patients 
requiring long- term- injectable agents for the 
treatment of TB?
What is the bottom line?
 ► This model of delivering care to patients 
receiving daily intramuscular drugs for TB could 
be feasible and cost saving for both users and 
providers.
Why read on?
 ► Training lay carers to give intramuscular 
injections to patients in their own homes may 
present a novel opportunity to improve the 
delivery of care to patients with recurrent or 
drug- resistant TB.
AbsTrACT
background People with recurrent or drug- resistant 
TB require long courses of intramuscular injections. We 
evaluate a novel system in which patient- nominated lay 
carers were trained to deliver intramuscular injections to 
patients in their own homes.
Methods a pragmatic, individually randomised non- 
inferiority trial was conducted at two hospitals in Malawi. 
adults starting TB retreatment were recruited. Patients 
randomised to the intervention received home- based 
care from patient- nominated lay people trained to 
deliver intramuscular streptomycin. Patients receiving 
standard care were admitted to hospital for 2 months 
of streptomycin. The primary outcome was successful 
treatment (alive and on treatment) at the end of the 
intervention.
results Of 456 patients screened, 204 participants 
were randomised. The trial was terminated early due to 
futility. at the end of the intervention, 97/101 (96.0%) 
in the hospital arm were still alive and on treatment 
compared with 96/103 (93.2%) in the home- based 
arm (risk difference −0.03 (95% ci −0.09 to 0.03); 
p value 0.538). There were no differences in the 
proportion completing 8 months of anti- TB treatment; 
or the proportion experiencing 2- month sputum 
culture conversion. The mean cost of hospital- based 
management was Us$1546.3 per person, compared to 
Us$729.2 for home- based management. home- based 
care reduced risk of catastrophic household costs by 
84%.
Conclusions although this trial failed to meet target 
recruitment, the available data demonstrate that training 
patient- nominated lay people has potential to provide a 
feasible solution to the operational challenges associated 
with delivering long- term- injectable drugs to people 
with recurrent or drug- resistant TB in resource- limited 
settings, and substantially reduce costs. Further data 
under operational conditions are required.
Trial registration number isrcTn05815615.
bACKground
Each year, approximately 700 000 people are 
treated for recurrent TB and a further 480 000 
for multidrug- resistant TB (MDR- TB).1 Treatment 
regimens for both of these groups currently involve 
long courses of daily injectable agents. In the case of 
TB retreatment, patients in countries with low prev-
alence of MDR- TB and no access to drug suscepti-
bility testing have been prescribed WHO ‘Category 
II retreatment regimen’.2 This is an 8- month course 
of oral antituberculous agents with the addition of 
intramuscular streptomycin for the first 60 days. 
Most patients with MDR- TB still receive at least 8 
months of injectables3 and even newer shortened 
regimens for MDR- TB include 4 months of inject-
able agents.4
Traditionally, patients have been admitted to 
hospital to receive injections, but long admissions 
are expensive for both users and providers5–7 
and associated with acquisition of nosoco-
mial infections.8 9 More recently, community- 
based approaches to delivering parenteral drugs 
have been encouraged. Models of delivery have 
involved either patients travelling daily from the 
community to a health facility, or a professional 
health worker visiting patients in their homes. 
Both models pose significant operational chal-
lenges,10 and a potential solution is for injections 
to be given to patients at home by a person living 
with them or close by.
Over recent years in industrialised countries, 
programmes of outpatient parenteral antibiotic 
therapy have been successfully instituted.11–13 
Evidence suggests that these services are safe, 
well received by users and highly cost effective.14 
Patients with diabetes in non- industrialised coun-
tries are prescribed insulin and successfully admin-
ister subcutaneous injections at home15; however, 
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Figure 1 Trial recruitment. MDR- TB, multidrug- resistant TB.
no model of carer- administered intramuscular treatment has yet 
been developed in a resource- limited setting.
In Malawi, ‘guardians’ have a well- established essential role in 
caring for people admitted to hospital. They are usually family 
members or friends who accompany patients, and perform a 
variety of tasks including basic care, assisting with medications 
and advocacy.16 The aim of this trial was to evaluate a novel 
method of delivering long- term injectables for TB in which 
patient- nominated lay people (guardians) were trained to 
administer daily intramuscular injections to patients in their own 
homes.
MeThods
Trial design and study participants
We conducted a pragmatic, individually randomised trial of 
hospital versus home- based care during the intensive phase of 
TB retreatment. Participants randomised to the intervention 
received home- based care from guardians trained to deliver 
intramuscular streptomycin. Participants randomised to receive 
standard care were admitted to hospital for 60 days, as was prac-
tice in Malawi.
The trial was conducted at two large hospitals in Malawi—
Queen Elizabeth Central Hospital (QECH) in Blantyre and 
Bwaila Hospital in Lilongwe. Consecutive patients registering 
for TB retreatment were recruited. Individuals were eligible if 
they were ≥16 years old, able to provide informed consent and 
able to identify a suitable guardian. People were excluded if they 
were identified as having MDR- TB or rifampicin- resistant TB; 
pregnant; or not planning to stay in the area.
study procedures
Standard practice in Malawi at the time of the trial was to 
admit all patients requiring streptomycin for the duration of 
the course. Patients admitted to hospital to start retreatment 
were identified each weekday by reviewing the TB and ward 
registers. Given the pragmatic nature of this trial, the diagnosis 
of TB was based on clinician assessment in usual operational 
conditions. Patients were asked to nominate a guardian for 
training. Consent was obtained separately from both patients 
and guardians.
A study nurse trained guardians in the technique of intramus-
cular injection, including injection procedure, sterile technique 
and disposal of sharps. Once the guardian was able to perform 
injections safely, they underwent a structured competency assess-
ment (see online supplementary file 1). Participants remained on 
the ward until randomisation.
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Table 1 Baseline characteristics of study participants
Total study population
n=204 (%)
hospital- based management
n=101 (%)
home- based management
n=103 (%)
Patient characteristics
Patient age (median, IQR) 36.5 (30.0–44.0) 37.0 (30.0–44.0) 36.0 (30.0–43.0)
Patient sex (% male) 142 (69.6) 77 (74.8) 65 (64.4)
TB class
  Pulmonary 182 (89.2) 84 (83.2) 98 (95.2)
  Extrapulmonary 22 (10.78) 17 (16.8) 5 (4.8)
TB category*
  Relapse 99 (48.5) 44 (43.6) 55 (53.4)
  TALTFU 5 (2.5) 2 (2.0) 3 (2.9)
  Fail 15 (7.4) 5 (5.0) 10 (9.7)
  Other 85 (41.7) 50 (49.5) 35 (34.0)
Sputum culture positive 80 (39.2) 38 (37.6) 42 (40.8)
HIV positive 164 (80.4) 87 (86.1) 77 (74.8)
Established on ART if HIV positive 131 (80.9) 70 (81.4) 61 (80.26)
CD4 count (cells/mm3; median, IQR) 177 (82–423) 161 (68–339) 225 (117–560)
No of previous TB episodes
  1 174 (85.3) 88 (87.1) 86 (83.5)
  2 28 (13.7) 12 (11.9) 16 (15.5)
  >2 2 (1.0) 1 (1.0) 1 (1.0)
Baseline Karnofsky Score (median, IQR) 90 (80–100) 90 (80–90) 90 (90–100)
History of alcohol excess† 47 (23.7) 21 (21.1) 26 (26.3)
Guardian characteristics
Guardian age (median, IQR) 32 (26–40) 33 (28–39) 30 (25–40)
Guardian sex (% male) 62 (30.4) 28 (27.7) 34 (33.0)
Guardian level of education
  None 4 (2.0) 4 (4.0) 0 (0.0)
  Standard 1–4 33 (16.2) 20 (19.8) 13 (12.6)
  Standard 5–8 52 (25.5) 26 (25.7) 26 (25.2)
  Form 1–2 42 (20.6) 18 (17.8) 24 (23.3)
  Form 3–4 45 (22.1) 20 (19.8) 25 (24.3)
  University 28 (13.7) 13 (12.9) 15 (14.6)
Guardian relationship to patient
  Spouse 74 (36.3) 37 (36.6) 37 (35.9)
  Sibling 56 (27.5) 28 (27.7) 28 (27.2)
  Parent 16 (7.8) 9 (2.9) 7 (6.8)
  Child 19 (9.3) 7 (6.9) 12 (11.7)
  Aunt/uncle 14 (6.9) 7 (6.9) 7 (6.8)
  Niece/nephew 9 (4.4) 3 (3.0) 6 (5.8)
  Friend/neighbour 16 (7.8) 10 (9.9) 6 (5.8)
*Standard WHO definitions of TB category: relapse=a patient previously treated for TB, declared cured or treatment completed, who is diagnosed again with smear or culture- 
positive TB; treatment after failure=a patient who is started on retreatment regimen after having failed previous treatment; treatment after loss to follow- up (TALTFU)=a patient 
who returns to treatment, positive bacteriologically, following interruption of treatment for 2 or more consecutive months; other previously treated=all previously treated cases 
that do not fit any of the above definitions http://www.who.int/tb/err/rr_final_forms_en.pdf.
†As defined by the Alcohol Use Disorders Identification Test.36
Randomisation
Randomisation was performed once the guardian had passed 
the competency assessment and the patient was fit for discharge. 
Participants were randomised to receive standard of care 
(hospital admission) or the intervention (home- based care) 
during the intensive phase of TB retreatment. Randomisation 
was carried out by a data team not otherwise involved in the 
conduct of the trial. Block randomisation in a ratio of 1:1 using 
variable block sizes of 4 or 6 was performed using a computer 
random number generator to produce an equal allocation ratio. 
Sequentially numbered opaque sealed envelopes were prepared 
by an independent person.
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Table 2 TB retreatment outcomes at 2 months
hospital- based management
n=101 (%)
home- based management
n=103 (%) P value rr (95% CI)
Alive and on TB treatment 97 (96.0) 96 (93.2) 0.538 0.97 (0.91 to 1.03)
Death 2 (2.0) 7 (6.8) 0.170 3.43 (0.73 to 16.13)
Loss to follow- up 2 (2.0) 0 (0.0) 0.244 Not applicable
RR, risk ratio.
Table 3 Details of deaths during the intensive phase of TB 
retreatment
details of event Location
home- based treatment arm
Stevens Johnsons syndrome 2 weeks after starting TB treatment, 
1 week after starting ART
Hospital
End stage heart failure with dilated cardiomyopathy; on treatment 
for presumed TB pericarditis
Hospital
Acute febrile illness with jaundice; treated for presumed bacterial 
sepsis
Hospital
Disseminated Kaposi Sarcoma, pancytopenia, ascites, splenomegaly Hospital
Headache, dysphasia, hemiparesis; treated for presumed cerebral 
toxoplasmosis
Hospital
Cryptococcal meningitis Hospital
Sudden death Community
hospital- based treatment arm
Died while receiving bowel prep for colonoscopy; presumed 
electrolyte imbalance
Hospital
Jaundice; presumed drug- induced liver injury Hospital
Follow-up of study participants
Participants in both arms were reviewed 1, 3, 5 and 7 weeks 
post randomisation. Reviews were conducted by a fieldworker 
with no formal clinical training. At each visit, an assessment 
for adverse events was performed, including assessments of 
hearing17; urine output; sciatic nerve injury; inspection of the 
injection site and documentation of new prescribed medica-
tions. For participants in the community, all used equipment 
was collected, and new equipment was delivered. At the first 
visit, guardians were required to pass another competency test 
to ensure competency was maintained in the home environment. 
Adherence was assessed at each visit by self- report and ‘vial 
count’ of streptomycin, equivalent to ‘pill count’ employed to 
assess adherence to antiretroviral therapy (ART) at HIV clinics in 
the region. Participants were provided with a form and asked to 
document each day that streptomycin had been given (see online 
supplementary file 2), in addition to the ‘TB card’ provided 
routinely for monitoring oral treatments. There was no formal 
assessment of adherence to HIV medications.
Adverse events monitoring
Given the nature of the intervention, standard definitions were 
adapted to encompass all possible consequences of home- based 
care (see online supplementary file 3). All patients presenting 
with clinical adverse events were reviewed by a study clinician 
(see online supplementary file 4).
outcomes
The primary outcome was successful treatment at the end 
of the 2- month intervention period. Successful treatment 
was defined as all those ‘still alive and on treatment having 
completed 2 months streptomycin injections’. Unsuccessful 
treatment included all patients died, lost to follow- up or 
outcome unknown.18
Predefined secondary endpoints included 2- month sputum 
culture conversion; programmatic TB outcome after 8 months 
of treatment; Karnofsky score at 2 months and mental health 
status at 2 months using a standard Self- Reporting Questionnaire 
(SRQ) validated in the local language.19
statistical analysis
The study was powered to detect non- inferiority in the interven-
tion arm. It was assumed that 87% of patients receiving standard 
of care and 82% of patients in the community would be alive 
and on treatment at the end of the 60- day intervention period, 
based on a review of records we performed of QECH data in 
2012. The sample size was calculated based on a non- inferiority 
margin of 6%. Using a one- sided alpha at a level of 0.05, in order 
to achieve a power of 80%, it was calculated that a sample size 
of 268 would be required. A single planned interim analysis was 
conducted after 130 had been recruited.
Primary analysis was based on intention to treat. Secondary 
per- protocol analysis was planned as a sensitivity analysis, and for 
this purpose protocol deviation was defined as any participant 
randomised to receive home- based management who was not 
discharged by the time they completed 60 days of streptomycin.
Efficacy outcomes are presented as proportions and compared 
using the Fishers exact test. The risk difference (RD) for unsuc-
cessful treatment outcome was estimated with 95% CIs. Risk 
ratios (RRs) with 95% CIs are presented for key secondary 
outcomes. There were no planned subgroup analyses. Analysis 
was performed using STATA V.12.1.
A within- trial cost- consequence analysis20 was undertaken 
from the societal perspective and included provider and user 
costs (see online supplementary file 5). Catastrohic cost was 
defined as healthcare costs equivalent to 10% of annual house-
hold income. Written informed consent was obtained from all 
study participants if literate, or with the signature of an indepen-
dent witness if illiterate.
resuLTs
study participants
Between June 2013 and February 2015, 456 patients starting 
TB retreatment regimen were screened. Of those screened, 278 
(60%) had guardians who began training to administer strepto-
mycin. After further withdrawals during the period of training, 
a total of 204 participants were randomised (figure 1). One 
patient was excluded from the analysis as they were randomised 
in error prior to being declared fit for discharge by a clinician. 
One hundred and forty- four were enrolled in Blantyre and the 
remaining 60 in Lilongwe.
A meeting of the Trial Steering Committee was held after 
200 patients had been recruited, at which it was decided to stop 
recruitment of the trial early due to futility. The event rate in the 
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Table 4 TB retreatment outcomes at 8 months
hospital- based management n=79 (%) home- based management n=83 (%) P value
rr
(95% CI)
Successful treatment 61 (77.2) 67 (80.7) 0.700 1.05 (0.89 to 1.23)
  Cure 26 (32.9) 41 (49.4) 0.039 1.50 (1.02 to 2.20)
  Complete 35 (44.3) 26 (31.3) 0.106 0.71 (0.47 to 1.06)
Fail 1 (1.2) 1 (1.2) 1.000 0.95 (0.06 to 14.96)
Death 11 (13.9) 13 (15.7) 0.827 1.12 (0.54 to 2.36)
Loss to follow- up 4 (5.1) 2 (2.4) 0.434 0.48 (0.09 to 2.53)
Transfer out 2 (2.5) 0 (0.0) 0.236 Not applicable
RR, risk ratio.
Table 5 Adverse events during the intensive phase of TB retreatment
hospital- based 
management
n=101
home- based 
management
n=103
Total adverse events 56 34
Serious adverse events 8 5
  Life- threatening illness 6 0
  Hospitalisation 0 5
  Significant disability 2 0
  Needle stick injury 0 0
Table 6 Costs of home- based management in the intensive phase of 
TB retreatment
hospital- based 
management
n=33
home- based 
management
n=32
Cost indicators
Total cost 2014 US$
47 936.6 21 875.6
outcome indicators
Number of patients completing 
intensive phase retreatment
31 30
Cost- difference indicators
Cost per patient completing 
intensive phase retreatment 2014 
US$ *
1546.3
(833.8–2764.1)
729.2
(341.5–1589.1)
Incremental cost difference
Cost per patient completing 
intensive phase retreatment 2014 
US$
−817.1
trial was lower than the 0.13 which had been projected: 0.0645 
in the intervention arm and 0.0426 in the control arm, so it was 
projected that in order to establish non- inferiority, at least 600 
participants would be required, and that this was not feasible 
given the resources available.
Characteristics of the study participants are summarised in 
table 1. The median age of patients was 36.5 years (IQR 30.0–
44.0 years), and 69.6% were men. The majority (89.2%) had 
pulmonary TB, classified most commonly as relapse (48.5%) or 
‘other’ (41.7%). The HIV prevalence was 80.4% and 131/164 
(80.9%) were on ART. The median length of time from start of 
TB treatment to discharge in the home- based group was 12 days 
(IQR 8–17 days).
successful completion of the intensive phase of Tb treatment
At the end of the intensive phase of treatment, 97 (96.0%) of 
patients in the hospital arm and 96 (93.2%) of patients in the 
home- based arm were still alive and on treatment (RD −0.03 
(95% CI −0.09 to 0.03); p value 0.538). Only an intention- to- 
treat analysis was performed, as all randomised patients received 
the form of treatment to which they are assigned. There were 
seven deaths in the home- based arm, and two in the hospital arm 
(RR 3.43; 95% CI 0.73 to 16.13) (table 2). Deaths were reviewed 
at a meeting of the Data and Safety Monitoring Board, and it was 
concluded that none were either directly or indirectly related 
to the intervention. Of the seven deaths which occurred in the 
home- based arm, six occurred after the patient had been read-
mitted to hospital (table 3). Two patients were lost to follow- up 
from hospital- based care, but none were lost to follow- up from 
home- based care.
secondary outcomes
End of TB treatment outcomes
Before the close of the study, 162 patients had registered TB 
treatment outcomes through the National TB Programme. 
There was no significant difference in the proportion of patients 
who successfully completed treatment in the home- based arm 
(80.7%) compared with the hospital arm (77.2%) of the trial 
(table 4).
Two-month sputum culture conversion
Of 80 patients who had sputum culture positive for Mycobac-
terium tuberculosis at the start of treatment, sputum culture 
was performed in 43 who were able to provide a sample after 
2 months of treatment. In the group receiving home- based care, 
21/23 (91.3%) went from sputum culture positive to sputum 
culture negative at 2 months, compared with 15/20 (75.0%) 
who culture converted in the hospital- based care group (RR 1.22 
(95% CI 0.91 to 1.61); p value 0.222).
Karnofsky score at the end of the intensive phase of treatment
The median Karnofsky score at the end of the intervention 
period was 100% in both groups. Of patients still alive at the 
end of the intensive phase of treatment, 84.4% in the home- 
based group and 79.2% in the hospital group had a Karnofsky 
score of 100%.
Mental health status at the end of the intensive phase of treatment
All but one of the 21 patients identified as having common 
mental health disorder at baseline no longer screened positive on 
the SRQ after 2 months of treatment. The patient who continued 
to screen positive had received hospital- based care.
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Table 7 Total user costs of hospital- based and home- based management during the intensive phase of TB retreatment
Mean cost us dollars (95% CI)
hospital- based management home- based management Mean difference*
Patient costs
During admission
  Direct medical† 0.7 (0.2 to 1.2) 0.4 (0.0 to 0.7) 0.3 (−0.2 to 1.0)
  Direct non- medical
   Food 69.8 (58.4 to 81.2) 26.7 (21.5 to 31.8) 43.1 (30.5 to 55.7)
   Transport 3.6 (1.6 to 5.7) 1.6 (0.5 to 2.6) 2.1 (−0.1 to 4.3)
   Linen 0.7 (0.1 to 1.3) 1.1 (−0.1 to 2.3) −0.5 (−1.8 to 0.9)
   Other out of pocket 11.9 (7.1 to 16.7) 4.7 (3.2 to 6.2) 7.2 (2.1 to 12.4)
  Indirect‡ 133.5 (111.6 to 155.4) 37.0 (28.7 to 45.3) 96.5 (73.2 to 119.7)
Health facility post discharge
  Direct medical and non- medical – 1.1 (0.3 to 2.0) −1.1 (−2.0 to -0.3)
  Indirect – 0.3 (0.1 to 0.5) −0.8 (−1.8 to 0.1)
Total patient costs 220.2 (189.8 to 250.8) 72.9 (60.5 to 85.3) 147.4 (114.1 to 180.6)
Guardian costs
During admission
  Direct non- medical
   Food 17.7 (11.1 to 24.2) 13.6 (9.2 to 17.9) 4.1 (−3.5 to 11.7)
   Transport 10.0 (5.6 to 14.3) 6.4 (4.1 to 8.8) 3.5 (−1.2 to 8.2)
   Linen 0.1 (−0.1 to 0.2) 0.1 (0.0 to 0.3) 0.0 (−0.3 to 0.2)
   Other out of pocket 2.9 (1.1 to 4.7) 1.6 (0.7 to 2.5) 1.3 (−0.7 to 3.4)
  Indirect 20.6 (8.4 to 32.9) 5.2 (2.8 to 7.7) 15.4 (3.1 to 27.7)
Health facility post discharge
  Direct non- medical – 1.0 (−0.6 to 2.7) −1.0 (−2.7 to 0.6)
  Indirect – 0.8 (−0.1 to 1.8) −0.8 (−1.8 to 0.1)
Total guardian costs 51.3 (31.8 to 70.8) 28.6 (21.5 to 36.2) 22.4 (2.2 to 42.7)
Total user costs 271.6 (234.4 to 308.7) 101.8 (85.1 to 118.4) 169.8 (128.9 to 210.7)
*Bootstrapped estimates of mean differences and 95% CI.
†Drugs and investigations purchased privately if unavailable in the public facility.
‡Lost income.
Adverse events
There were 56 adverse events in 36 patients receiving hospital- 
based care and 34 adverse events in 20 patients receiving 
home- based care (table 5). One patient reported a missed dose 
of streptomycin and two patients missed a single dose by ‘vial 
count’, but there was no episode which met the predefined 
criteria for an adherence event. There were no needle stick inju-
ries in either arm. There were eight serious adverse events in 
the hospital arm and five in the home- based arm. Both adverse 
events resulting in disability were a consequence of ototoxicity.
economic evaluation
Data about user costs were available for 188 trial participants, 
and data about provider costs were collected for a subgroup of 
65 participants (32 receiving home- based care and 33 receiving 
hospital- based care).
The total cost of hospital- based management was US$1546.3 
per person compared with US$729.2 per person who received 
home- based management, giving a cost difference of US$ 
−817.1 (table 6). The total mean cost to users in the hospital 
arm was US$271.6 (234.4–308.7), compared with US$101.8 
(85.1–118.4) for those who receiving home- based care (mean 
difference 169.8; 95% CI 128.9 to 210.7) (table 7). Total 
provider costs were US$498.0 (425.6–570.4) per patient who 
received home- based care, compared with US$1100.3 (1040.8–
1159.8) per patient who received hospital- based care (see online 
supplementary file 6).
The risk of catastrophic household costs was 34.1% for partic-
ipants in the home- based arm and 85.9% for those managed in 
hospital (RR 0.40; 95% CI 0.29 to 0.54) (see online supple-
mentary file 7). Applying a definition of catastrophic cost at 
20% of annual household income, home- based management 
was associated with an 11.4% risk of catastrophic cost whereas 
hospital- based management was associated with a 62.0% risk of 
catastrophic cost (RR 0.16; 95% CI 0.08 to 0.41) (see online 
supplementary file 7). The reduction in risk of catastrophic cost 
was seen irrespective of wealth quartile, gender or HIV status.
dIsCussIon
This trial failed to meet target recruitment and was therefore 
insufficiently powered to demonstrate non- inferiority of the 
intervention; however, the available data do not demonstrate a 
difference in clinical outcomes between people receiving inject-
able treatments for TB delivered by lay carers and the traditional 
hospital- based model of care. Additionally, catastrophic patient 
costs were largely avoided by home- based care.
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The RD between the two groups in the primary outcome was 
only 3%. However, the CIs around this estimate reached 9%; 
therefore, non- inferiority cannot be concluded at the predefined 
margin of 6%. These figures are open for discussion. First, a 
non- inferiority margin of 6% was conservative, with many other 
trials setting margins of 10%–15%.21–24 Second, the point esti-
mate of 3% difference in risk is low and the absolute risk of 
patients failing to complete 2 months of home- based retreatment 
was only 7%, much lower than previous estimates of death or 
loss to follow- up during the first 2 months of TB retreatment.
There were seven deaths in the home- based arm of the study, 
compared with only two in the hospital arm. The mortality rate 
was not statistically different between the two groups; however, 
the circumstances of these deaths still need to be carefully exam-
ined. A higher mortality may have been as a direct consequence 
of guardians administering injections, but none of the deaths 
were related to unsafe administration of an intramuscular injec-
tion such as sepsis. Additionally, there is no evidence that adher-
ence to treatment in the home- based arm was a problem, as both 
measures of adherence suggested very few missed doses of strep-
tomycin; the rate of sputum culture conversion at 2 months was 
similar in both groups; and all of the deaths were due to condi-
tions other than TB. Another possible reason for an increased 
death rate in the community is that patients at home had less 
medical attention during the intensive phase of treatment. Some 
evidence for this may be suggested by the higher number of 
adverse events in the hospital arm. However, any prescription 
of medication by a physician was classified as an adverse event 
and it is well recognised that overprescription of antibiotics and 
other drugs by clinicians to patients in hospital is common.25 26 
An indirect effect of home- based care also seems unlikely given 
that, of the seven deaths in people randomised to the home- 
based arm, six happened only following readmission to hospital. 
In 5 out of 6 of these patients, the death took place only after 
they had been receiving appropriate treatment in hospital for at 
least 7 days. If this model of care is to be more widely adopted, 
it will require close ongoing evaluation.
There was no difference between the two study arms in terms 
of successful 8- month completion of TB treatment (80.7% in 
the home- based model vs 77.2% in the hospital- based model), 
which is operationally the most significant outcome from the 
perspective of global TB control. Additionally, the rate of 
8- month cure was significantly higher (49.4% vs 32.9%, RR 1.50 
(1.02 to 2.20; p value 0.039)) and the rate of 2- month culture 
conversion was non- significantly higher in the home- based arm 
(91.3% in the home vs 75.0% in the hospital). The mechanisms 
by which home- based care may be contributing to improving 
some outcome indicators may be through more ownership of 
health decisions, fewer economic consequences and ultimately 
better adherence to treatment.27 28
The study has a number of limitations. Most importantly, the trial 
was stopped early because of futility, which impacts the strength of 
the data. Efforts had been made to predict the expected event rate 
by conducting a review of the QECH TB register prior to starting 
the study, but the observed event rate was lower than expected. It is 
likely that the main reason for this was the requirement for partici-
pants to have a guardian able and willing to undertake delivery of the 
injectable. This resulted in exclusion before randomisation of 102 
patients (see figure 1). Patients without guardians or with guardians 
unwilling to take on the responsibility of injecting may have been 
less likely to have stable lifestyles. In this way, the trial probably 
recruited a more stable cohort of patients than those assessed in 
the record review. Additionally, it is common for outcomes in a 
trial setting to be better than in routine practice due to increased 
input from the study team.29 30 Although a proportion of patients 
were not recruited because they were never clinically stable enough 
to be discharged, it was never intended for the intervention to be 
applicable to all patients prescribed TB retreatment, and even under 
routine conditions only those well enough to go home would be 
considered for home- based management. Finally, the study was 
conducted at only two sites in Malawi, both in large urban areas, 
and so results are not necessarily generalisable to other contexts.
The trial also has a number of strengths. As far as possible, the 
study was pragmatic and provides data for policy- makers that 
are relevant to routine operational conditions31 32, for example: 
reviews conducted by research staff with experience equivalent 
to that of a health surveillance assistant27; eligibility criteria 
including all patients clinically fit for discharge without addi-
tional investigations which would not be available in routine 
practice; no therapeutic drug monitoring to assess adherence 
in the community; and a primary outcome measure which is 
routinely recorded in TB reporting systems. Additionally, a trial- 
based economic evaluation provides robust data demonstrating 
that home- based management is associated with significant 
reductions in both provider and user costs, and qualitative eval-
uation (published elsewhere33) demonstrates the acceptability of 
lay carers delivering injectables.
The reduction in provider costs from US$1100 to US$489 
potentially has an enormous impact on health systems in coun-
tries like Malawi, where the total expenditure on health per 
capita is US$93.28 Additionally, the intervention reduced the 
risk of catastrophic household costs ≥10% by 60%, and the risk 
of catastrophic household costs ≥20% by 84%. There are now 
strong data demonstrating that household catastrophic costs in 
relation to TB are associated with poorer clinical TB outcomes,34 
and one of the targets of the WHO EndTB strategy is that ‘no 
TB- affected families should experience catastrophic costs due to 
TB’.35 This study was underpowered for clinical outcome, and 
another large randomised controlled trial would be costly and 
time consuming. However, the data demonstrate compelling 
health economic benefits for both providers and users. If TB 
programmes consider adopting this model, further data should 
be collected under operational conditions in order to monitor 
ongoing clinical safety and economic benefit.
Recent guidelines encourage a move away from the use of 
long- term- injectable agents for TB. However, the complete 
phase out of Category II regimen is still dependent on the avail-
ability of rapid molecular- based drug- susceptibility testing and 
resolution of the debate surrounding the best treatment for 
isoniazid monoresistant TB. Similarly, despite recent communi-
cations from WHO, the global use of fully oral regimens for all 
people with MDR- TB is still some way off given the financial and 
operational issues which still surround these regimens.
If targets to reduce catastrophic household expenditure asso-
ciated with TB are to be met, the issue of how to deliver long- 
term injectable agents to stable patients in the community needs 
to be addressed. This study presents a novel method of adminis-
tering injections to patients in their homes as part of their long- 
term TB care. Training patient- nominated lay people to deliver 
injectables may offer a sustainable opportunity for home- based 
management of patients with recurrent or drug- resistant TB in 
resource- limited settings but further operational data to support 
the findings of this study are needed.
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